Drs. Holloway and Dietrich discuss the biological and clinical significance of HER2+ receptors in these diverse malignancies, collectively referred to as pan-tumors, as well as the implications of HER2 that are crucial for advancing approaches to diagnosis, treatment, and patient care across various cancer types.
